ATE218364T1 - Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung - Google Patents

Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung

Info

Publication number
ATE218364T1
ATE218364T1 AT99948725T AT99948725T ATE218364T1 AT E218364 T1 ATE218364 T1 AT E218364T1 AT 99948725 T AT99948725 T AT 99948725T AT 99948725 T AT99948725 T AT 99948725T AT E218364 T1 ATE218364 T1 AT E218364T1
Authority
AT
Austria
Prior art keywords
pulmonary administration
insulin preparations
stable concentrated
concentrated insulin
formulations
Prior art date
Application number
AT99948725T
Other languages
English (en)
Inventor
Svend Havelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE218364T1 publication Critical patent/ATE218364T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT99948725T 1998-10-16 1999-10-15 Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung ATE218364T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801327 1998-10-16
PCT/DK1999/000556 WO2000023098A1 (en) 1998-10-16 1999-10-15 Stable concentrated insulin preparations for pulmonary delivery

Publications (1)

Publication Number Publication Date
ATE218364T1 true ATE218364T1 (de) 2002-06-15

Family

ID=8103620

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01126054T ATE277630T1 (de) 1998-10-16 1999-10-15 Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
AT99948725T ATE218364T1 (de) 1998-10-16 1999-10-15 Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01126054T ATE277630T1 (de) 1998-10-16 1999-10-15 Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung

Country Status (22)

Country Link
EP (2) EP1121144B1 (de)
JP (1) JP4212240B2 (de)
KR (1) KR100617286B1 (de)
CN (1) CN1210058C (de)
AT (2) ATE277630T1 (de)
AU (1) AU758146B2 (de)
BR (1) BR9914585A (de)
CA (1) CA2346969A1 (de)
CZ (1) CZ20011134A3 (de)
DE (2) DE69920767T2 (de)
DK (2) DK1172114T3 (de)
ES (2) ES2177323T3 (de)
HU (1) HUP0104111A3 (de)
IL (2) IL142011A0 (de)
NO (1) NO323365B1 (de)
PL (1) PL197504B1 (de)
PT (2) PT1172114E (de)
RU (1) RU2218935C2 (de)
TW (1) TWI223597B (de)
UA (1) UA65636C2 (de)
WO (1) WO2000023098A1 (de)
ZA (1) ZA200102105B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
NZ519403A (en) * 2001-06-21 2005-03-24 Pfizer Prod Inc Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
WO2003094956A1 (en) * 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US8765124B2 (en) 2003-02-28 2014-07-01 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
MXPA05009565A (es) * 2003-03-11 2005-12-02 Novo Nordisk As Preparaciones farmaceuticas que comprenden insulina estabilizada con acido.
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
EP2505593A1 (de) * 2005-12-28 2012-10-03 Novo Nordisk A/S Zusammensetzungen enthaltend acyliertes Insulin und Zink und Verfahren zur Herstellung dieser Zusammensetzungen
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
BRPI0717098B8 (pt) 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
EP2514412A1 (de) * 2007-04-30 2012-10-24 Novo Nordisk A/S Hochkonzentrierte Insulinlösungen und -zusammensetzungen
EP2502618A3 (de) 2007-04-30 2012-10-03 Novo Nordisk A/S Verfahren zum Trocknen einer Proteinzusammensetzung, getrocknete Proteinzusammensetzung und pharmazeutische Zusammensetzung mit dem getrockneten Protein
CN101677947B (zh) * 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
KR20110004366A (ko) 2008-03-18 2011-01-13 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
AU2011235959C1 (en) * 2008-06-13 2013-10-10 Eli Lilly And Company PEGylated insulin lispro compounds
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 glp-1 효능제의 병용물
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
EP3345593B1 (de) 2009-11-13 2023-09-06 Sanofi-Aventis Deutschland GmbH Pharmazeutische zusammensetzung umfassend despro36exendin-4(1-39)-lys6-nh2 und methionin
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー/エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI608847B (zh) 2011-08-29 2017-12-21 賽諾菲阿凡提斯德意志有限公司 用於控制糖尿病二型病患血糖的醫藥組合物
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
ES2594303T3 (es) 2012-04-11 2016-12-19 Novo Nordisk A/S Formulaciones de insulina
CN104870469A (zh) * 2012-12-26 2015-08-26 沃克哈特有限公司 药物组合物
CN105142661B (zh) 2013-04-03 2019-08-16 赛诺菲 通过长效胰岛素制剂治疗糖尿病
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
CN115154591B (zh) 2016-12-16 2023-04-14 诺和诺德股份有限公司 含胰岛素的药物组合物
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP7518149B2 (ja) * 2019-07-12 2024-07-17 ノヴォ ノルディスク アー/エス 高濃度インスリン製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
BR9709844A (pt) * 1996-06-20 1999-08-10 Novo Nordisk As Preparação aquosa de insulina formulação farmacêutica parenteral usos de um carboidrato n o-redutor ou reduzido e de manitol sorbitol xilitol inositol trealose sacarose ou qualquer sua mistura e processo de fabricação de uma preparação de insulina
ATE220555T1 (de) * 1997-03-20 2002-08-15 Novo Nordisk As Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
WO1998042368A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin

Also Published As

Publication number Publication date
CN1323219A (zh) 2001-11-21
DE69920767D1 (de) 2004-11-04
PL197504B1 (pl) 2008-04-30
PT1121144E (pt) 2002-11-29
EP1172114B1 (de) 2004-09-29
ZA200102105B (en) 2001-10-12
ES2177323T3 (es) 2002-12-01
BR9914585A (pt) 2001-07-03
CA2346969A1 (en) 2000-04-27
NO20011842D0 (no) 2001-04-10
JP2002527487A (ja) 2002-08-27
DK1172114T3 (da) 2005-01-24
NO323365B1 (no) 2007-04-10
AU6188999A (en) 2000-05-08
IL142011A0 (en) 2002-03-10
EP1172114A2 (de) 2002-01-16
EP1121144B1 (de) 2002-06-05
DE69901726D1 (de) 2002-07-11
ATE277630T1 (de) 2004-10-15
IL142011A (en) 2007-07-04
JP4212240B2 (ja) 2009-01-21
HUP0104111A2 (hu) 2002-04-29
AU758146B2 (en) 2003-03-13
PT1172114E (pt) 2005-02-28
EP1121144A1 (de) 2001-08-08
ES2228728T3 (es) 2005-04-16
DE69920767T2 (de) 2006-02-02
KR100617286B1 (ko) 2006-08-30
EP1172114A3 (de) 2003-07-23
DE69901726T2 (de) 2002-12-19
RU2218935C2 (ru) 2003-12-20
CZ20011134A3 (cs) 2001-08-15
UA65636C2 (uk) 2004-04-15
CN1210058C (zh) 2005-07-13
WO2000023098A1 (en) 2000-04-27
DK1121144T3 (da) 2002-09-23
KR20010075631A (ko) 2001-08-09
PL347210A1 (en) 2002-03-25
NO20011842L (no) 2001-06-15
TWI223597B (en) 2004-11-11
HUP0104111A3 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
ATE218364T1 (de) Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
DE60224284D1 (de) Stabile formulierung von modifiziertem glp-1
DE69914934D1 (de) Stabile wässrige insulinzubereitungen ohne phenol und kresol
CY1110547T1 (el) Συμπυκνωμενα πρωτεϊνικα σκευασματα μειωμενου ιξωδους
NO985981D0 (no) Insulinpreparater som inneholder NaCl
DE69531314D1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
DE69808695D1 (de) Stabile Insulinformulierungen
NO970051L (no) Vandige risperidon formuleringer
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
NO331082B1 (no) Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
PT1121145E (pt) Preparacoes de insulina contendo mentol e destinadas a administracao via pulmonar
DK1283051T3 (da) Stabile insulinformuleringer
GR1001511B (el) Στεροειδείς συν?έσεις.
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
WO2003033014A3 (de) Neue verwendung von lungensurfactant
ATE286716T1 (de) Pharmazeutische formulierungen enthaltend salmeterol
DE69940708D1 (de) Pharmazeutische Zubereitungen zur parenteralen Verabreichung enthaltend Epothilon
IL140127A0 (en) Process for the preparation of optically active 1,4-benzodixoane-2-carboxylic acid and derivatives thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee